...
search icon
cytk-img

Cytokinetics Inc Share Price

CYTK
NSQ
$66.26
+$1.22
(1.88%)
1D
Industry: Biotechnology Sector: Health Care

Cytokinetics Inc Analyst Forecast

Cytokinetics Inc Share Price Chart

Cytokinetics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.95B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.08M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.55
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$29.31 L
$70.98 H
$66.26

About Cytokinetics Inc, Common Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Cytokinetics Inc Stock Returns

Time FrameCYTKSectorS&P500
1-Week Return6.29%-1.08%-1.38%
1-Month Return4.63%-0.47%-1.81%
3-Month Return1.13%2.13%1.38%
6-Month Return79.66%17.04%5.68%
1-Year Return59.2%6.56%11.74%
3-Year Return51.04%16.78%65.15%
5-Year Return217.03%34.34%73.68%
10-Year Return838.53%137.88%260.03%

Cytokinetics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue55.83M70.43M94.59M7.53M18.47M[{"date":"2020-12-31","value":59.02,"profit":true},{"date":"2021-12-31","value":74.46,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.96,"profit":true},{"date":"2024-12-31","value":19.53,"profit":true}]
Cost of Revenue96.95M159.94M240.81M330.12M339.41M[{"date":"2020-12-31","value":28.56,"profit":true},{"date":"2021-12-31","value":47.12,"profit":true},{"date":"2022-12-31","value":70.95,"profit":true},{"date":"2023-12-31","value":97.26,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(41.12M)(89.51M)(146.22M)(322.59M)(320.93M)[{"date":"2020-12-31","value":-4112300000,"profit":false},{"date":"2021-12-31","value":-8951000000,"profit":false},{"date":"2022-12-31","value":-14622500000,"profit":false},{"date":"2023-12-31","value":-32259300000,"profit":false},{"date":"2024-12-31","value":-32093400000,"profit":false}]
Gross Margin(73.66%)(127.09%)(154.59%)(4284.10%)(1737.22%)[{"date":"2020-12-31","value":-73.66,"profit":false},{"date":"2021-12-31","value":-127.09,"profit":false},{"date":"2022-12-31","value":-154.59,"profit":false},{"date":"2023-12-31","value":-4284.1,"profit":false},{"date":"2024-12-31","value":-1737.22,"profit":false}]
Operating Expenses52.82M96.80M177.98M173.61M215.31M[{"date":"2020-12-31","value":24.53,"profit":true},{"date":"2021-12-31","value":44.96,"profit":true},{"date":"2022-12-31","value":82.66,"profit":true},{"date":"2023-12-31","value":80.63,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(93.94M)(186.31M)(324.20M)(496.20M)(536.25M)[{"date":"2020-12-31","value":-9394300000,"profit":false},{"date":"2021-12-31","value":-18631300000,"profit":false},{"date":"2022-12-31","value":-32420200000,"profit":false},{"date":"2023-12-31","value":-49620500000,"profit":false},{"date":"2024-12-31","value":-53624800000,"profit":false}]
Total Non-Operating Income/Expense(66.69M)(58.00M)(104.57M)(60.95M)(88.26M)[{"date":"2020-12-31","value":-6669400000,"profit":false},{"date":"2021-12-31","value":-5800200000,"profit":false},{"date":"2022-12-31","value":-10456700000,"profit":false},{"date":"2023-12-31","value":-6095000000,"profit":false},{"date":"2024-12-31","value":-8825600000,"profit":false}]
Pre-Tax Income(127.29M)(215.31M)(388.95M)(526.24M)(589.53M)[{"date":"2020-12-31","value":-12729000000,"profit":false},{"date":"2021-12-31","value":-21531400000,"profit":false},{"date":"2022-12-31","value":-38895500000,"profit":false},{"date":"2023-12-31","value":-52624400000,"profit":false},{"date":"2024-12-31","value":-58952600000,"profit":false}]
Income Taxes36.84M27.06M13.60M11.72M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":73.43,"profit":true},{"date":"2022-12-31","value":36.9,"profit":true},{"date":"2023-12-31","value":31.82,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(164.13M)(242.37M)(402.55M)(537.97M)-[{"date":"2020-12-31","value":-16413500000,"profit":false},{"date":"2021-12-31","value":-24237000000,"profit":false},{"date":"2022-12-31","value":-40255200000,"profit":false},{"date":"2023-12-31","value":-53796810500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(104.58M)(202.42M)(332.27M)(526.73M)(589.53M)[{"date":"2020-12-31","value":-10457700000,"profit":false},{"date":"2021-12-31","value":-20242200000,"profit":false},{"date":"2022-12-31","value":-33227400000,"profit":false},{"date":"2023-12-31","value":-52672800000,"profit":false},{"date":"2024-12-31","value":-58952600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(127.29M)(215.31M)(388.95M)(526.24M)(589.53M)[{"date":"2020-12-31","value":-12729000000,"profit":false},{"date":"2021-12-31","value":-21531400000,"profit":false},{"date":"2022-12-31","value":-38895500000,"profit":false},{"date":"2023-12-31","value":-52624400000,"profit":false},{"date":"2024-12-31","value":-58952600000,"profit":false}]
EPS (Diluted)(2.01)(2.83)(4.22)(5.45)(5.26)[{"date":"2020-12-31","value":-201,"profit":false},{"date":"2021-12-31","value":-283,"profit":false},{"date":"2022-12-31","value":-422,"profit":false},{"date":"2023-12-31","value":-545,"profit":false},{"date":"2024-12-31","value":-526,"profit":false}]

Cytokinetics Inc Ratios

Cytokinetics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CYTK
Cash Ratio 6.77
Current Ratio 6.88

Cytokinetics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CYTK
ROA (LTM) -24.93%
ROE (LTM) -572.15%

Cytokinetics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CYTK
Debt Ratio Lower is generally better. Negative is bad. 1.36
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.36

Cytokinetics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CYTK
Trailing PE NM
Forward PE NM
P/S (TTM) 91.18
P/B 60.31
Price/FCF NM
EV/R 93.81
EV/Ebitda NM
PEG NM

FAQs

What is Cytokinetics Inc share price today?

Cytokinetics Inc (CYTK) share price today is $66.26

Can Indians buy Cytokinetics Inc shares?

Yes, Indians can buy shares of Cytokinetics Inc (CYTK) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CYTK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cytokinetics Inc be purchased?

Yes, you can purchase fractional shares of Cytokinetics Inc (CYTK) via the Vested app. You can start investing in Cytokinetics Inc (CYTK) with a minimum investment of $1.

How to invest in Cytokinetics Inc shares from India?

You can invest in shares of Cytokinetics Inc (CYTK) via Vested in three simple steps:

  • Click on Sign Up or Invest in CYTK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cytokinetics Inc shares
What is Cytokinetics Inc 52-week high and low stock price?

The 52-week high price of Cytokinetics Inc (CYTK) is $70.98. The 52-week low price of Cytokinetics Inc (CYTK) is $29.31.

What is Cytokinetics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cytokinetics Inc (CYTK) is

What is Cytokinetics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cytokinetics Inc (CYTK) is 60.31

What is Cytokinetics Inc dividend yield?

The dividend yield of Cytokinetics Inc (CYTK) is 0.00%

What is the Market Cap of Cytokinetics Inc?

The market capitalization of Cytokinetics Inc (CYTK) is $7.95B

What is Cytokinetics Inc's stock symbol?

The stock symbol (or ticker) of Cytokinetics Inc is CYTK

How Can Investors Use Cytokinetics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Cytokinetics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Cytokinetics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Cytokinetics Inc shares for Indian investors?

When investing in Cytokinetics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Cytokinetics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Cytokinetics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Cytokinetics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Cytokinetics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top